Litcius/Paper detail

A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma

Pengcheng He, Haibo Liu, Bryan Zimdahl, Jie Wang, Minna Luo, Qi Chang, Fangzhou Tian, Ni Fan, Duo Yu, Huasheng Liu, Li‐Mei Chen, Huaiyu Wang, Mei Zhang, Stephan A. Grupp, Cheng Liu

2022Journal of Cancer Research and Clinical Oncology16 citationsDOIOpen Access PDF

Topics & Concepts

HematologyRefractory (planetary science)MedicineLymphomaCD19Internal medicineOncologyAntibodyB cellImmunologyCancer researchBiologyAstrobiologyCAR-T cell therapy researchMonoclonal and Polyclonal Antibodies ResearchCutaneous lymphoproliferative disorders research